CoreCap Advisors’s vTv Therapeutics VTVT Stock Holding History

CoreCap Advisors’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.39K	Hold	45	–	–	﹤0.01%	2600
2026 Q2	$1.69K	Hold	45	–	–	﹤0.01%	2581
2026 Q1	$1.78K	Hold	45	–	–	﹤0.01%	2441
2025 Q4	$1.8K	Hold	45	–	–	﹤0.01%	2498
2025 Q3	$1.05K	Hold	45	–	–	﹤0.01%	2476
2025 Q2	$675	Hold	45	–	–	﹤0.01%	2472
2025 Q1	$779	Buy	+45	New	+$752	﹤0.01%	2579
2022 Q4	$249	Buy	+9	New	+$298	﹤0.01%	2253

Other funds holding VTVT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

CoreCap Advisors's VTVT Position: Q3 2026 in Review

CoreCap Advisors held its vTv Therapeutics (VTVT) position steady in Q3 2026 at 45 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

CoreCap Advisors first reported a position in VTVT in Q4 2022 and has held it in 8 quarters since. The position peaked at $1.8K in Q4 2025. 11 funds tracked by Wall St. Rank hold VTVT as of Q3 2026.

CoreCap Advisors held 45 shares of vTv Therapeutics worth $1.39K as of Q3 2026.
CoreCap Advisors left its vTv Therapeutics share count unchanged in Q3 2026.
vTv Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2600 holding.
CoreCap Advisors first reported a position in vTv Therapeutics in Q4 2022 and has held it in 8 quarters since.
CoreCap Advisors's vTv Therapeutics position peaked at $1.8K in Q4 2025.
11 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.